Total
0
Shares
Mesoblast (ASX:MSB) - CEO, Silviu Itescu - The Market Herald
CEO, Silviu Itescu
Sourced: The Australian
  • Mesoblast (MSB) has received U.S. Food and Drug Administration (FDA) clearance to treat COVID-19 patients with its remestemcel-L product
  • In particular, remestemcel-L will be used to treat patients with acute respiratory distress syndrome which is the most common cause of death relating to COVID-19
  • This product has already proven effective in improving lung function in similar conditions
  • Recent clinical trials showed remestemcel-L to either completely cure or significantly improve functional outcomes for all patients
  • Mesoblast has spiked 30.5 per cent on the market this morning and shares are trading for $1.76 each

Mesoblast (MSB) has received U.S. Food and Drug Administration (FDA) clearance to treat COVID-19 patients with its remestemcel-L product.

In particular, it will be used to treat acute respiratory distress syndrome (ARDS) which is common in patients with COVID-19.

"The FDA clearance provides a pathway in the United States for use of remestemcel-L in patients with COVID-19 ARDS, where the prognosis is very dismal, under both expanded access compassionate use and in a planned randomised controlled trial," Chief Medical Officer Dr Fred Grossman commented.

Remestemcel-L is an investigational therapy that is made up of mesenchymal stem cells (cells that come from different parts of the body) that are taken from an unrelated donor.

In a recent clinical trial that tested the stem cells against COVID-19 related pneumonia, the treatment was shown to either completely cure or significantly improve functional outcomes for all patients.

Additionally, remestemcel-L has been proven to significantly enhance lung function in patients with chronic obstructive pulmonary disease (COPD), a group of lung diseases that make it difficult to breathe.

Given the similarities between COPD and ARDS caused by COVID-19, Mesoblast has made the connection that remestemcel-L is likely to have a similar outcome on patients with COVID-19 as it did those with COPD.

Originally, remestemcel-L was used to treat steroid-refractory acute versus host. disease, a condition in which the body rejects bone marrow transplants.

This product is now available in Japan under the name Temcell.

Mesoblast has spiked 30.5 per cent on the market this morning and shares are trading for $1.76 each at 10:53 am AEST.


Subscribe


MSB by the numbers
More From The Market Herald
Micro X (ASX:MX1) - CEO, Peter Rowland - The Market Herald

" Micro-X (ASX:MX1) ships $500K of x-ray machines over May

X-ray tech specialist Micro-X (MX1) has filled $500,000 worth of orders for its Carestream DRX Revolution Nano product in the month of May
Skin Elements (ASX:SKN) - Executive Chairman, Peter Malone - The Market Herald

" Skin Elements (ASX:SKN) SE Formula 99.99pc effect against coronavirus

Skin Elements’ (SKN) natural plant-based SE Formula has been proven 99.99 per cent effective against Feline coronavirus, a surrogate of COVID-19. Both the...
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) receives A$3.6M from French Govt.

Biotech company, Immutep (IMM) has received $3.6 million (€2,173,454) from the French Government.
Acrux (ASX:ACR) - Managing Director & CEO, Michael Kotsanis - The Market Herald

" Acrux (ASX:ACR) signs sales and distribution agreement with TruPharma

Acrux (ACR) has announced its subsidiary, Acrux DDS, has entered a 10-year exclusive sales, marketing and distribution agreement with TruPharma in the U.S.